Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$17K Sell
131
-28
-18% -$3.28K ﹤0.01% 167
2026
Q1
$19K Buy
159
+1
+0.6% +$115 ﹤0.01% 162
2025
Q4
$17K Sell
158
-90
-36% -$8.45K ﹤0.01% 167
2025
Q3
$21K Sell
248
-21
-8% -$1.73K ﹤0.01% 164
2025
Q2
$22K Sell
269
-6,284
-96% -$500K ﹤0.01% 153
2025
Q1
$593K Buy
6,553
+6,437
+5,549% +$601K 0.01% 105
2024
Q4
$12K Buy
+116
New +$12K ﹤0.01% 113
2023
Q3
Sell
-6,000
Closed -$692K 148
2023
Q2
$692K Buy
6,000
+500
+9% +$56.8K 0.01% 115
2023
Q1
$589K Buy
+5,500
New +$594K 0.01% 121

Other funds holding MRK

Clal Insurance's MRK Position: Q2 2026 in Review

Clal Insurance reduced its Merck (MRK) stake by 18% in Q2 2026, selling an estimated $3.28K and leaving 131 shares worth $17K. The position accounts for ﹤0.01% of the portfolio, ranked #167.

Clal Insurance first reported a position in MRK in Q1 2023 and has held it in 9 quarters since. The position peaked at $692K in Q2 2023. 3,844 funds tracked by Wall St. Rank hold MRK as of Q2 2026.

  • Clal Insurance held 131 shares of Merck worth $17K as of Q2 2026.
  • Clal Insurance sold 28 Merck shares in Q2 2026, an estimated $3.28K.
  • Merck made up ﹤0.01% of Clal Insurance's portfolio in Q2 2026, its #167 holding.
  • Clal Insurance first reported a position in Merck in Q1 2023 and has held it in 9 quarters since.
  • Clal Insurance's Merck position peaked at $692K in Q2 2023.
  • 3,844 funds tracked by Wall St. Rank held Merck as of Q2 2026.

Based on Clal Insurance's 13F filing for Q2 2026, filed 13 Aug 2026.